Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: Comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model

Biopharmaceutics and Drug Disposition

Volumn 22, Issue 1, 2001, Pages 1-14

  Tsukamoto, Yuko ^a   Kato, Yukio ^a   Ura, Masako ^b   Horii, Ikuo ^b   Ishikawa, Tohru ^a   Ishitsuka, Hideo ^b   Sugiyama, Yuichi ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOXIFLURIDINE; DRUG METABOLITE; FLUOROURACIL; PLASMA PROTEIN; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ENZYME KINETICS; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; SIMULATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; COLONIC NEOPLASMS; CYTOSOL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRODRUGS; SUBCELLULAR FRACTIONS; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035188291     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.250     Document Type: Article

References (19)

1. Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells
2. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
3. A comparative study between 5′-DFUR and Tegafur in recurrent breast cancer
4. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, Capecitabine
5. Tumor-selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
6. 4-pentyloxycarbonyl-5′-deoxy-5-fluoropyrimidine (capecitabine)
7. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
8. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: The mechanism for tumor-selective accumulation of 5-FU
9. Pharmacokinetic study of capecitabine in monkeys and mice: Species differences in distribution of the enzyme responsible for its activation to 5-FU
10. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models
11. Physiological parameters in laboratory animals and humans
12. Prediction of intestinal first-pass effect of phenacetine in the rat from enzyme kinetic data - Correlation with in vivo data using mucosal blood flow
13. Influence of pH on the uptake of 5-fluorouracil into isolated tumor cell
14. Analysis of nonlinear and non-steady state hepatic extraction with the dispersion model using the finite difference method
15. Blood flow, oxygen and nutrient supply, and metabolic microviroment of human tumors: A review
16. Liver dihydropyrimidine dehydrogenase activity in human, cynomolgus monkey, rhesus monkey, dog, rat and mouse
17. Pharmacologically guided phase I clinical trials based upon preclinical drug development
18. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity
19. Hepatic and intestinal metabolism of Indinavir, an HIV protease inhibitor, in rats and human microsomes, major role of CYP 3A